公开(公告)号：US20250108008A1

公开(公告)日：2025-04-03

申请号：US18762297

申请日：2024-07-02

Applicant: BioNTech SE

Inventor： Heinrich Haas ,  Sebastian Hörner ,  Isaac Hernan Esparza Borquez ,  Thomas Michael Hiller ,  Ferdia Bates

IPC: A61K9/127 ,  A61K31/713 ,  A61K48/00 ,  B82Y5/00

Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.

公开(公告)号：US12263215B2

公开(公告)日：2025-04-01

申请号：US17209926

申请日：2021-03-23

Applicant: BIONTECH SE

Inventor： Steve Pascolo

IPC: A61K39/39 ,  A61K35/13 ,  A61K39/00

Abstract: The present invention relates to particles comprising RNA, in which the RNA is associated with a cationic polymer or lipid or with both a cationic polymer and lipid, wherein the RNA comprises a cytotoxic nucleotide or cytotoxic nucleotide analog and/or the RNA is covalently attached to a cytotoxin, pharmaceutical compositions containing said particles and pharmaceutical uses of the particles and pharmaceutical compositions. The particles of the present invention are particularly useful as an immunostimulating medicament capable to block proliferation or induce death in dividing cells such as tumor cells.

公开(公告)号：US20250057944A1

公开(公告)日：2025-02-20

申请号：US18702860

申请日：2022-10-21

Applicant: BioNTech SE ,  Consejo Superior de Investigaciones Científicas (CSIC)

Inventor： Jorge Moreno Herrero ,  Heinrich Haas ,  Stephanie Erbar ,  José Manuel García Fernández ,  Juan Manuel Benito Hernández ,  Jose Lopez Fernandez

IPC: A61K39/385 ,  A61K39/00 ,  A61K39/04 ,  A61K39/145 ,  A61P37/04

Abstract: The present disclosure provides complexes comprising a cationic oligosaccharide and an RNA, wherein the cationic oligosaccharide comprises a plurality of cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6, and a ratio of N/P in the complex is less than 20:1

公开(公告)号：US20250011797A1

公开(公告)日：2025-01-09

申请号：US18737443

申请日：2024-06-07

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Florian Eberle ,  Ugur Sahin ,  Andreas Kuhn ,  Britta Vallazza ,  Mustafa Diken

IPC: C12N15/68 ,  A61K39/00 ,  A61K48/00 ,  C12N15/67 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00

Abstract: The present invention relates to nucleic acid molecules containing poly(dA:dT) regions which are stabilized in E.coli, methods of propagating such nucleic acid molecules in E.coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly(dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

公开(公告)号：US20240355417A1

公开(公告)日：2024-10-24

申请号：US18618412

申请日：2024-03-27

Applicant: BioNTech SE ,  InstaDeep Ltd

Inventor： Alexander Muik ,  Ugur Sahin ,  Asaf Poran ,  Alexandra Walls ,  Yunguan Fu ,  Rafal Okuniewski ,  Nicolas Winfried Pfeuffer

IPC: G16B20/50 ,  G16B40/20 ,  G16B45/00 ,  G16B50/30 ,  G16H50/80

CPC classification number: G16B20/50 ,  G16B40/20 ,  G16B45/00 ,  G16B50/30 ,  G16H50/80

Abstract: The present disclosure, among other things, provides technologies for identifying, characterizing, and/or monitoring variant sequences of a particular reference infections agent. Among other things, systems, methods, and architectures described herein provide visualization and decision support tools that can, e.g., facilitate decision making processes by local authorities and improve pandemic response in terms of, e.g., resource allocation, policy making, and speed tailored vaccine development. The present disclosure also provides tools for analyzing circulating variants to predict mutations likely to increase immune evasion of infectious agents.

公开(公告)号：US20240321387A1

公开(公告)日：2024-09-26

申请号：US18289424

申请日：2022-05-04

Applicant: BioNTech SE ,  InstaDeep Ltd

Inventor： Alexander Muik ,  Asaf Poran ,  Yunpeng Liu ,  Ugur Sahin ,  Karim Beguir ,  Marcin Skwark ,  Thomas Pierrot ,  Yunguan Fu

IPC: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

CPC classification number: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

Abstract: A method is provided for identifying a number of variants of concern of a reference disease associated immunogen. The method uses a language model to perform inference on data representing each of a plurality of variants and data representing the reference immunogen. For each of the plurality of variants and the reference immunogen, a characteristic vector is derived from an output feature map of a hidden layer of the language model. For each of the plurality of variants, a measure of distance is generated for the variant that includes calculating a measure of distance between the characteristic vector of the variant and the characteristic vector of the reference immunogen. A semantic change score is calculated for each variant based on the generated measure of distance for that variant. A variant of the reference immunogen is selected based, at least in part, on the generated the semantic change scores.

公开(公告)号：US20240263232A1

公开(公告)日：2024-08-08

申请号：US18420361

申请日：2024-01-23

Applicant: BioNTech SE

Inventor： Ugur SAHIN ,  Martin SUCHAN ,  Barbara SCHRÖRS ,  Martin LÖWER ,  Petra OEHM

IPC: C12Q1/6876 ,  C12Q1/686

CPC classification number: C12Q1/6876 ,  C12Q1/686 ,  C12Q2600/156

Abstract: This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.

公开(公告)号：US12054485B2

公开(公告)日：2024-08-06

申请号：US17590550

申请日：2022-02-01

Applicant: BIONTECH SE

Inventor： Christophe Henry

IPC: C07D471/04 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00

Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

公开(公告)号：US11987569B2

公开(公告)日：2024-05-21

申请号：US17669117

申请日：2022-02-10

Applicant: BIONTECH SE

Inventor： Christophe Henry

IPC: A61P35/00 ,  C07D401/04 ,  C07D471/04

CPC classification number: C07D401/04 ,  A61P35/00 ,  C07D471/04

Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

公开(公告)号：US20240124609A1

公开(公告)日：2024-04-18

申请号：US18363136

申请日：2023-08-01

Applicant: BioNTech SE

Inventor： Wolfgang Scholz ,  Ritsuko Sawada

IPC: C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574

CPC classification number: C07K16/3084 ,  A61K39/39558 ,  A61K45/06 ,  G01N33/57492 ,  A61K2039/505

Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.